Blurbs

Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ocuphire Pharma (OCUPResearch Report), Aridis Pharmaceuticals (ARDSResearch Report) and Acurx Pharmaceuticals (ACXPResearch Report) with bullish sentiments.

Ocuphire Pharma (OCUP)

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Ocuphire Pharma, with a price target of $20.00. The company’s shares closed last Wednesday at $3.76.

According to TipRanks.com, Caufield is a 5-star analyst with an average return of 29.6% and a 66.7% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, 4D Molecular Therapeutics, and Aldeyra Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocuphire Pharma with a $20.75 average price target.

See today’s best-performing stocks on TipRanks >>

Aridis Pharmaceuticals (ARDS)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Aridis Pharmaceuticals today and set a price target of $10.00. The company’s shares closed last Wednesday at $1.23.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 20.1% and a 36.0% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Blue Water Vaccines, Inc., Finch Therapeutics Group, and Achieve Life Sciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aridis Pharmaceuticals with a $6.00 average price target.

Acurx Pharmaceuticals (ACXP)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Acurx Pharmaceuticals, with a price target of $14.00. The company’s shares closed last Wednesday at $3.98.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 19.7% and a 44.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Paratek Pharmaceuticals.

Currently, the analyst consensus on Acurx Pharmaceuticals is a Moderate Buy with an average price target of $13.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OCUP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed